---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-281581"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:54:34.637657+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sensei discontinues solnerstotug, starts strategic review; workforce cut 65%

## Summary
- Discontinued solnerstotug development; Board considering sale, merger, or wind-down.
- Workforce cut ~65% to preserve cash; small team retained for strategic review.
- Cash $25.0M as of Sep 30, 2025, down from $41.3M at Dec 31, 2024.
- Q3 2025 net loss $4.6M (vs $7.3M YoY); R&D $2.5M (vs $4.6M YoY).

## SEC filing metadata
- accession: 0001193125-25-281581
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/0001193125-25-281581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-281581
- JSON: https://secwatch.observer/filing/0001193125-25-281581.json
- Plain text: https://secwatch.observer/filing/0001193125-25-281581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.